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Abstract 23	
High-grade non-muscle invasive bladder cancer (HG-NMIBC) is a clinically unpredictable 24	
disease with greater risks of recurrence and progression relative to their low-intermediate-25	
grade counterparts. The molecular events, including those affecting the epigenome, that 26	
characterise this disease entity in the context of tumour development, recurrence and 27	
progression, are incompletely understood. We therefore interrogated genome-wide DNA 28	
methylation using HumanMethylation450 BeadChip-arrays in 21 primary HG-NMIBC 29	
tumours relative to normal bladder controls. Using strict inclusion-exclusion criteria we 30	
identified 1,057 hypermethylated CpGs within gene promoter-associated CpG islands, 31	
representing 256 genes. Bisulphite Pyrosequencing validated the array data and examined 32	
25 array-identified candidate genes in an independent cohort of 30 HG-NMIBC and 18 low-33	
intermediate-grade NMIBC. These analyses revealed significantly higher methylation 34	
frequencies in high-grade tumours relative to low-intermediate-grade tumours for the 35	
ATP5G2, IRX1 and VAX2 genes (p<0.05), and similarly significant increases in mean levels 36	
of methylation in high-grade tumours for the ATP5G2, VAX2, INSRR, PRDM14, VSX1, 37	
TFAP2b, PRRX1, and HIST1H4F genes (p<0.05). Although inappropriate promoter 38	
methylation was not invariantly associated with reduced transcript expression, a significant 39	
association was apparent for the ARHGEF4, PON3, STAT5a, and VAX2 gene transcripts 40	
(p<0.05). Herein, we present the first genome-wide DNA methylation analysis in a unique 41	
HG-NMIBC cohort, showing extensive and discrete methylation changes relative to normal 42	
bladder and low-intermediate-grade tumours. The genes we identified hold significant 43	
potential as targets for novel therapeutic intervention either alone, or in combination, with 44	
more conventional therapeutic options in the treatment of this clinically unpredictable 45	
disease. 46	
Key words: High-grade Non-Muscle Invasive Bladder Cancer, Epigenetics, Methylation, 47	
HumanMethylation450 BeadChip Array, Gene Expression 48	
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Introduction 49	
Bladder cancer is the ninth most common cancer worldwide.1 The majority of bladder 50	
cancers are transitional cell carcinomas (TCC), of which 70-80% are non-muscle invasive 51	
(NMIBC) at presentation.2 Poorly differentiated ‘high-grade’ (HG)-NMIBC is a clinically 52	
important sub-type, accounting for approximately 10-15% of all NMIBCs at presentation.3, 4, 53	
These high-grade tumours are typically more aggressive than their low- and intermediate-54	
grade counterparts, manifest by higher rates of recurrence and progression to invasive and 55	
metastatic disease despite intensive and prolonged intravesical treatment.5, 6  56	
 57	
The majority of NMIBCs are thought to be consequent to, and represent initiation and 58	
progression from, a complex interplay between sporadic, environmental, and heritable risk 59	
factors, including those that impact upon genetic and epigenetic pathways. NMIBCs and 60	
muscle invasive bladder cancers (MIBCs) have been shown to develop independently (‘the 61	
two pathway model’) on the basis of gain of function fibroblast growth factor receptor 3 62	
(FGFR3) mutations in NMIBC, and loss of function mutations in retinoblastoma 1 (RB1) and 63	
tumour protein 53 (p53) in MIBC,7-10 and have been shown to evolve from different cell 64	
types. 11, 12 However, the molecular pathways responsible for the evolution, outgrowth and 65	
progression of HG-NMIBC have not been subject to comprehensive study or investigation; 66	
indeed, it is currently unclear whether HG-NMIBCs arise as a discrete disease entity, 67	
whether they represent step-wise progression from low-intermediate-grade NMIBC tumours, 68	
or whether they sit at a molecular crossroads between NMIBC and MIBC.7, 13 11 This 69	
uncertainty is illustrated by the findings that high-grade tumours harbour abnormalities in 70	
common with low-intermediate-grade NMIBC, such as mutations of FGFR3 and/or rat 71	
sarcoma viral oncogene homolog (RAS) pathway genes14, 15, but also display extensive 72	
genetic instability and compromised regulation of vital cellular processes more in keeping 73	
with MIBC.14, 16 74	
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Epigenetic modifications are frequently implicated in the development of human 75	
malignancies, and in these cases, are typically apparent as inappropriate gene promoter 76	
CpG island DNA methylation, histone tail modification(s), aberrant expression of micro- and 77	
long non-coding-RNAs, and less frequently, loss of gene body/intergenic methylation.17, 18 78	
These heritable modifications, or epimutations, impact upon gene expression either alone or 79	
in combination, and promote tumour evolution and/or progression by suppressing the 80	
expression of growth inhibiting and/or apoptosis promoting genes, and less frequently by 81	
leading to relaxed control of expression of growth promoting genes.17, 19, 20 82	
Epigenetic modifications and associated gene silencing have been shown in NMIBC, and 83	
specific patterns of DNA methylation, histone modifications and microRNA expression have 84	
been reported as associated with tumour growth characteristics, patient/clinical outcomes 85	
and with field defect phenomena.21, 22 However, the majority of these reports have described 86	
epigenetic changes in heterogeneous populations of NMIBC, with an abundance of low- and 87	
intermediate-grade tumours relative to high-grade tumours. With the exception of our recent 88	
candidate-gene study23 and a single report investigating the Myopodin A gene24, HG-89	
NMIBCs have not been considered as a discrete entity for the investigation of epigenetic 90	
modifications. 91	
In this study, we interrogated DNA methylation on a genome-wide scale using methylation 92	
BeadChip-array technology, in a unique cohort of HG-NMIBCs. Through comparisons with 93	
methylation levels and gene-expression in low/intermediate-grade tumours, we extend the 94	
current understanding of bladder cancer tumourigenesis and identify potential epigenetic 95	
mechanisms implicated in the development of high-grade NMIBC, and those that might 96	
represent novel therapeutic drug-targets. 97	
  98	
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Results 99	
Technical Validation of array by Pyrosequencing: 100	
Subsequent to array processing, normalisation and peak-based correction (see patients and 101	
methods), a technical validation was performed by comparing array-derived β-values with 102	
Pyrosequencing-derived methylation values. Across 120 data-points (5 CpGs, 24 samples) 103	
encompassing a broad range of array β-values, a strong positive correlation was found 104	
between the methylation values (Spearman’s rank correlation r=0.912, p<0.00001; 105	
Supplemental Figure S1). 106	
 107	
In-house filtering criteria: 108	
CpGs showing differential methylation in HG-NMIBC relative to normal bladder controls were 109	
identified following a series of stringent filtering criteria, as described previously and shown 110	
in Figure 1.25, 26 On the basis of these criteria, a total of 1,057 CpGs, representing 256 111	
genes, were identified as hypermethylated (≥0.4 β-value increase) in 15 or more of the 21 112	
high-grade tumours, relative to their mean values in the normal bladder controls. 113	
 114	
Hierarchical clustering analyses: 115	
The filtered dataset was next subject to unsupervised hierarchical cluster analysis (Figure 116	
2): the high-grade tumours cluster independently from the normal bladder control samples. 117	
In these cases, methylation is barely detectable within the normal bladder samples, whereas 118	
15 or more of the high-grade tumours show inappropriate methylation across all 1,057 CpG 119	
dinucleotides, spanning 256 gene-promoter-associated CpG islands (Supplemental Table 120	
S2).  121	
 122	
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Independent validation by Pyrosequencing: 123	
We next selected 25 genes for independent validation by Pyrosequencing on the basis of 124	
their frequent methylation in the discovery cohort that comprised 21 high-grade tumours. 125	
These analyses revealed similar frequencies and mean levels of methylation as those 126	
apparent from the BeadChip array for 24 of the 25 genes. As further confirmation, we 127	
extended the Pyrosequence analyses to an independent investigation cohort of 30 HG-128	
NMIBC tumours. Similar frequencies and mean levels of methylation between the discovery 129	
and investigation cohorts reinforced our confidence in the array-derived data (Supplemental 130	
Table S3). At this stage, and to assess for potential confounders, we assessed associations 131	
between patient demographic data and methylation patterns across these 25 genes, using 132	
separate multivariate models. No correlations were identified in these analyses, suggesting 133	
demographic factors did not significantly impact upon the methylation patterns identified 134	
(data not shown). 135	
 136	
Differential subtype-specific promoter methylation in NMIBC: 137	
We next determined methylation across the 25 genes described above in HG-NMIBC 138	
relative to that apparent in low-intermediate-grade tumours and in comparison to normal 139	
bladder controls (Supplemental Table S4). Similar to other groups27 28, we displayed these 140	
methylation data, across the high-grade and low-intermediate-grade tumours and normal 141	
controls, by heatmap (Figure 3). This demonstrated heterogeneous patterns of methylation 142	
across the 51 high- and 18 low-intermediate-grade tumours relative to the normal bladder 143	
controls. Gene-specific differences in methylation were apparent between the high-grade 144	
tumours and their low-intermediate-grade counterparts on visual inspection. Closer 145	
examination of these data showed that the differences appeared to impact on either the 146	
relative frequency and/or the mean levels of methylation between these tumour subtypes. As 147	
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examples of these differences, the ten most differentially methylated genes are shown in 148	
Table 1.  149	
 150	
Methylation frequencies in high- and low-intermediate-grade tumours: 151	
For ten of the genes we took forward for further analyses (ATP5G2, HIST1H4F, INSRR, 152	
IRF8, IRX1, PRDM14, PRRX1, TFAP2b, VAX2 and VSX1), there was an higher frequency of 153	
methylation in high-grade tumours versus low-intermediate grade tumours (Table 1). 154	
Moreover, the increases were statistically significant for the ATP5G2, VAX2 and IRX1 genes 155	
(p<0.05), and approached significance for the INSRR, IRF8, PRDM14 and VSX1 genes.  156	
 157	
Mean levels of methylation in high- and low-intermediate-grade tumours: 158	
The mean levels of methylation in the high-grade tumours were next assessed by 159	
Pyrosequencing (right-sided panel of Table 1, and Figure 4); for eight of the ten genes, 160	
mean levels of methylation were significantly greater in high-grade tumours relative to their 161	
low-intermediate-grade counterparts. In addition, and as low-intermediate-grade tumours 162	
were not subject to array analyses relative to normal bladder, further pairwise-testing was 163	
performed. This analysis identified significant differences between mean levels of 164	
methylation in the low-intermediate-grade tumours and normal bladder in four of the ten 165	
genes assessed. The range, distribution and mean levels of methylation are shown in 166	
Figure 4, and show for each of the genes, a stepwise trend toward increasing methylation 167	
from normal bladder to low-intermediate and high-grade tumours. 168	
 169	
Methylation-Associated Changes in Gene Expression: 170	
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Across the high-grade NMIBC tumours, sufficient sample was available for gene expression 171	
analyses for 17 of the 25 genes. With the exception of the ARHGEF4 gene, promoter-172	
associated CpG island methylation was negatively correlated with transcript expression for 173	
all genes assessed (data not shown). Furthermore, the presence of promoter methylation 174	
was significantly correlated with reduced transcript expression for the PON3, STAT5a and 175	
VAX2 genes (Spearman’s correlation coefficients -0.60, -0.50 and -0.48 respectively, all 176	
p<0.05). Conversely, promoter methylation was significantly positively correlated with gene 177	
transcript expression for the ARHGEF4 gene (Spearman’s correlation coefficient 0.62, 178	
p<0.05). Figure 5 shows the expression levels for these four genes across the high-grade 179	
tumours. 180	
 181	
Gene Ontology analysis of inappropriately methylated genes: 182	
Gene Ontology analyses of the 256 differentially methylated genes identified ‘over-183	
representation’ of multiple categories of biological processes, molecular functions and 184	
pathways. In particular, highly significant over-representation was identified for specific 185	
biological processes, including regulation of RNA polymerase II activity and DNA 186	
transcription, and for pathways involving cell adhesion and PI3K-Akt signalling 187	
(Supplemental Table S5). 188	
  189	
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Discussion 190	
In common with most other tumour types, bladder cancers harbour epigenetic aberrations 191	
which are frequently apparent as inappropriate DNA methylation.8, 22, 29 However, reports are 192	
limited and largely confined to heterogeneous patient cohorts of NMIBC or MIBC;30 despite 193	
their clinical importance, high-grade NMIBC tumours are rarely investigated as a discrete 194	
entity in the context of disease and/or subtype-specific epigenetic modifications.23 To 195	
address this, we performed genome-wide analyses of DNA methylation using BeadChip 196	
array technology in high-grade NMIBC, comprising a discrete cohort of tumours recruited at 197	
initial presentation. This analysis, the first ‘450K array’ interrogation in bladder cancer, 198	
revealed multiple and novel frequently differentially methylated genes in these tumours 199	
relative to normal bladder. Through Pyrosequence analysis of sodium bisulphite converted 200	
DNA, we extended our analyses to include independent cohorts of high- and low-201	
intermediate-grade tumours. These investigations confirmed the array-derived data for the 202	
high-grade tumours, and showed them as harbouring significantly increased frequencies 203	
and/or mean levels of gene-specific methylation relative to low-intermediate-grade tumours. 204	
Moreover, for some of the genes investigated, a significant inverse correlation between 205	
promoter methylation and gene expression levels was apparent and suggests their potential 206	
as targets for therapeutic intervention.29 31 32 207	
 208	
Initially we performed a technical validation of the discovery cohort data by Pyrosequence 209	
analysis of converted DNA.25 33 34 In common with previous reports and across multiple 210	
genes, these analyses confirmed and reinforced the array-derived data.34 35 36 These 211	
analyses also showed that for the majority of regions investigated, methylation extended to 212	
include contiguous promoter-associated CpG sites. On the basis of  previous reports from 213	
our own and other groups,37 38 we employed stringent criteria (β-value differences ≥0.4) to 214	
identify differentially methylated genes across multiple CpG sites; such criteria are more 215	
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consistently associated with bona fide changes in methylation, and are more likely to show 216	
associations with gene expression.37, 39 40, 41 217	
The analysis of the discovery cohort of high-grade NMIBC identified 1,057 CpGs, across 256 218	
gene-promoter-associated CpG islands. Cluster analysis and heat map display of these 219	
regions revealed extensive and frequent differential methylation in the tumours relative to 220	
normal bladder controls. As our study represents the first 450K analysis of high-grade 221	
bladder cancer a direct ‘like-for-like’ comparisons of our findings with those of other groups 222	
was not possible; however, the number of differentially methylated sites we identified 223	
appeared to be lower than those previously reported in other tumour types.42 43 Potential 224	
explanations for these findings are the tumour type per se and/or the stringency of our 225	
inclusion-exclusion criteria and definition of differential methylation.44  226	
For the genes identified, we performed gene ontology and KEGG pathway analyses. In 227	
these cases we identified significant over-representation of genes in processes and 228	
pathways previously reported by other groups as subject to epigenetically-mediated 229	
dysregulation in tumour development. For examples, these included transcription and cell 230	
signalling and adhesion45-47, suggesting possible similar roles in high-grade bladder tumours, 231	
and their validity as targets for further investigation. 232	
We next extended our investigation of multiple novel genes to an independent cohort of 233	
high-grade tumours, and a cohort of low-intermediate-grade tumours for comparison. Similar 234	
frequencies and mean levels of methylation, as determined by Pyrosequence analysis, were 235	
apparent within the discovery and investigation cohorts of high-grade tumours, suggesting 236	
our approach for the identification of candidates by array analysis was robust. Interestingly, 237	
many of the genes identified as novel and differentially methylated were also inappropriately 238	
methylated in low-intermediate-grade tumours. However, and despite the absence of genes 239	
as being exclusively associated with either high- or low-intermediate-grade tumours, the 240	
frequency and mean levels of gene-promoter methylation in the high-grade tumours were 241	
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significantly higher than in the low-intermediate-grade tumours. Indeed, similar observations 242	
with respect to differences in the frequencies of methylation between high- and low-grade 243	
bladder tumours were first suggested by Ibragimova et al.47 Similar subtype and/or grade-244	
associated differences have been reported in other tumour types including, pituitary, breast, 245	
and colon cancer subtypes.37, 48, 49 In our analysis of NMIBC it remains unclear whether the 246	
increase in frequency and/or mean levels of methylation in the more aggressive tumours 247	
represents a more rapid accumulation of epigenetic changes during tumour progression, or 248	
reflects distinct epigenetic pathways of tumour development and outgrowth.50, 51 Our findings 249	
may therefore reflect either of the described scenarios in the more aggressive (high-grade) 250	
tumours and suggests that these tumours are either consequent to progression from low-251	
intermediate-grade tumours, or are the progeny of aberrations in distinct epigenetic 252	
pathways within these NMIBC subtypes. Moreover, the identification of different patterns of 253	
methylation between tumours represents an important area for future investigation. In this 254	
case, methylation may hold promise as an ‘at diagnosis’ biomarker of long-term tumour 255	
outcome, similar to that described in colorectal, breast and lung cancers. 52-54 256	
Although many of the novel genes we identified have not been previously reported in 257	
bladder cancer, their inappropriate methylation, accompanied with gene-silencing, has been 258	
reported in the context of other tumour types and suggests potential roles as tumour 259	
suppressor genes.55, 56 57 To determine associations between methylation and gene 260	
expression, we confined our studies to genes showing frequent and/or high mean levels of 261	
methylation. For the majority of gene-transcripts we investigated, promoter methylation was 262	
negatively correlated with reduced transcript expression, although not significantly so (data 263	
not shown). However, as described by our own and other groups, this may reflect a 264	
passenger-driver phenomenon where, in the ‘passenger’ context, gene expression is not 265	
directly influenced by the observed epigenetic modification(s).58	 59	 However, for four of 266	
seventeen transcripts we examined, significant correlations between methylation and 267	
transcript expression were apparent. In these cases, and for the PON3, STAT5a and VAX2 268	
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genes, promoter methylation was significantly associated with reduced gene expression, 269	
whilst the converse was true for the ARHGEF4 gene. Such associations are similar to those 270	
described previously in multiple other cancers and in NMIBC.	20, 21 43	 Indeed, for two of these 271	
genes, PON3 and STAT5a, previous studies in mice and cell-line models have described 272	
potential tumour suppressor roles.60 61 If this is the case, then these genes may represent 273	
important targets for further studies of functional the significance of methylation and reduced 274	
expression in a bladder tumour context, including in-vitro investigations of de-methylating 275	
agents designed to restore gene expression. 276	
In summary, we have presented the first comprehensive genome-wide DNA methylation 277	
analysis of NMIBC in a unique cohort of high-grade tumours. The study has reported an 278	
increase in the frequency and/or mean levels of methylation at gene promoter-associated 279	
CpG islands in high-grade tumours relative to their low-intermediate-grade tumour 280	
counterparts, that in some cases is associated with reduced gene expression. These 281	
findings suggest that epigenetic modifications, alone or in combination with other 282	
aberrations, are causal in the development and/or progression of this tumour type. Further 283	
studies are required to assess the functional significance of epigenetic changes in HG-284	
NMIBC; however, we suggest that the genes identified hold significant potential as targets 285	
for novel therapeutic interventions alone, or in combination, with conventional therapeutic 286	
options in the treatment of this clinically unpredictable disease. 287	
 288	
 289	
  290	
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Patients and methods 291	
Human tissue samples 292	
Primary tumour and normal bladder tissues used were provided by the Bladder Cancer 293	
Prognosis Programme (BCPP, National Research Ethics Service East Midlands - Derby 294	
06/MRE04/65.)62, the University of Birmingham Human Biomaterials Resource Centre 295	
(National Research Ethics Service (North West 5): 09/H1010/75), and the University 296	
Hospitals of North Midlands NHS Trust (National Research Ethics Service (South Central – 297	
Oxford C): 12/SC/0725). All samples were confirmed histologically as normal bladder 298	
urothelium (control, n=4), G3pT1 TCC (high-grade: discovery cohort n=21, investigation 299	
cohort n=30), and G1/2 pTa/1 TCC (low/intermediate-grade: n=18). As previously 300	
described23, patients received repeat bladder tumour resection (TURBT), cystectomy and/or 301	
intra-vesical therapy as recommended by European Association of Urology guidelines.63 All 302	
samples (details are provided in Supplemental Table S1) were stored at -80oC prior to 303	
nucleic acid extraction, as described below. 304	
 305	
DNA extraction and bisulphite modification 306	
Genomic DNA was extracted from tumour and control tissues using a standard phenol-307	
chloroform procedure 64, then bisulphite-converted using the EZ DNA Methylation Gold kit 308	
(Zymo Research) as we have previously described.37 Bisulphite-conversion of DNA was 309	
confirmed in all cases by successful PCR using primers specific to bisulphite-converted DNA 310	
(primer sequences in Supplemental Table S6). To increase the relative amount and stability 311	
of bisulphite-converted DNA, whole-genome amplification (WGA) was performed as 312	
previously described.37 313	
 314	
 315	
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Illumina 450K Methylation Bead-Array Analyses 316	
Bisulphite-converted DNA from 21 bladder tumours and three normal controls was 317	
hybridised to Infinium-based HumanMethylation450 BeadChip arrays (Illumina, San Diego, 318	
CA, USA) to quantify DNA methylation at approximately 480,000 CpG positions across the 319	
genome, representing more than 21,000 RefSeq genes. In this case, normal bladder was 320	
used as control for consistency with previous array analyses 35, 47, 65, and also to permit 321	
comparisons with earlier reports of non-muscle invasive bladder cancer. Arrays were 322	
processed according to the manufacturer’s instructions (performed by Barts and the London 323	
Genome Centre, UK), as described by us previously.66  324	
Raw array data were processed using GenomeStudio software and the bioinformatical 325	
platform ‘NIMBL’, as we 67, 68 and others69 have described. For each probe, the methylation 326	
status was reported as a methylation ‘β-value’, where ‘β’ is defined as the ratio of the 327	
methylated signal intensity over the summed intensity of the methylated and unmethylated 328	
signals + 100.40 β-values range from 0 (unmethylated) to 1 (fully methylated). NIMBL was 329	
used to perform ‘peak-based’ correction, to adjust for potential differences in array probe-330	
type sensitivity previously reported33; all comparative analyses of high-grade tumours to 331	
normal bladder controls, were performed on peak-based corrected β-values, as described by 332	
us previously.68  333	
Each array passed quality control assessment based upon the performance of internal 334	
controls and the distribution of β-values across all array CpGs. As previously described68, 335	
and represented by step 1 of Figure 1, we excluded all CpGs for which any of the 24 336	
samples displayed: (i) probe detection p-values >0.05 (unreliable probe data), or (ii) missing 337	
β-values (preventing analyses of all samples). We also excluded all CpG loci on allosomes 338	
(reducing confounding gender-based methylation differences). We used a series of stringent 339	
filtering criteria, shown in Figure 1 and described in the Results section, to identify 340	
15	
	
inappropriate methylation, defined as a β-value difference ≥0.4, in tumour samples relative 341	
to the mean of the normal bladder controls. 342	
 343	
Unsupervised hierarchical clustering using average linkage criteria was performed using 344	
Genesis software (v1.7.6).70 Gene Ontology (GO) analyses were performed using 345	
http://geneontology.org/ and http://gather.genome.duke.edu/, and Kyoto Encyclopaedia of 346	
Genes and Genomes (KEGG) analyses with http://www.genome.jp/kegg/ online platforms, 347	
respectively. Bonferroni correction71 was employed in all GO and KEGG pathway analyses. 348	
 349	
Technical validation of Methylation Bead-Chip Array Data 350	
Five CpG loci encompassing a broad range of β-values derived from 450k array analyses, 351	
were assessed by Pyrosequencing (described below), using identical samples, to 352	
independently validate the array data (β-values vs. methylation %). Correlation between the 353	
methods was assessed across a total of 120 CpGs using Spearman’s rank correlation, as 354	
shown in Supplemental Figure S1. Primer sequences are provided in Supplemental Table 355	
S6. 356	
 357	
Pyrosequencing™ of sodium bisulphite-converted DNA 358	
Validation of array data (discovery cohort) and further quantitative assessment of 359	
methylation in the independent (investigation) tumour cohort were performed by 360	
Pyrosequencing of sodium bisulfite-converted DNA, as previously described by us66, using a 361	
PyroMark Q24 Pyrosequencer, PyroMark Q24 Software 2.0 and PyroMark Gold Q24 362	
Reagents. Dependent on the specific gene, and the density of CpGs within their promoter-363	
associated CpG island, between five and nine consecutive CpG sites were assessed. 364	
Promoter methylation was defined in tumours if the mean level of methylation across the 365	
assessed CpG island was greater either than four standard deviations (4SD), or 20% above, 366	
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the mean of the normal controls.37 The number of tumours methylated for any given gene 367	
describes the frequency of methylation, whereas the mean percentage methylation per se of 368	
all of the CpGs surveyed within a gene describes the mean level of methylation. 369	
 370	
Quantitative RT-PCR 371	
Total RNA was extracted from control and tumour samples using a standard guanidinium 372	
thiocyanate-phenol-chloroform protocol 72. Complementary DNA (cDNA) was synthesised as 373	
described previously73. Thermal cycling using SYBR Green was as previously described74, 374	
with target genes normalised to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as 375	
the endogenous control gene (Supplemental Table S6). Relative quantification of transcript 376	
expression was performed using the 2-∆∆ cycle threshold (CT) method75, and as previously 377	
described76. Reduced transcript expression in a tumour was defined where expression was 378	
at least 3-fold lower than the mean level of expression observed in control samples; the 379	
converse was true for increased transcript expression.37 38 77 380	
 381	
Non-Array Informatics and statistics. 382	
STATA (version 8, Stata Corporation, College Station, TX) was used to analyse methylation 383	
and gene expression data in tumour and normal cohorts using Fisher’s exact tests 384	
(frequency of methylation), Student’s t-tests (mean level of methylation), and Spearman 385	
correlation coefficients (associations between methylation and gene expression). p-values 386	
<0.05 were considered statistically significant. 387	
  388	
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Figure Legends 636	
 637	
Figure 1. Array filtering steps. Summary of the steps implemented for the identification of 638	
CpGs hypermethylated in HG-NMIBC. The initial filtering steps (*) included exclusion of non-639	
significant probe data, probes with missing data and probes located on allsomes.  640	
RefSeq (National Center for Biotechnology Information Reference Sequence Database). 641	
CpG island based upon the UCSC genome browser definition from Gardiner-Garden and Frommer78.  642	
 643	
Figure 2. Unsupervised hierarchical clustering analysis of the 1,057 gene promter-644	
associated hypermethylated CpGs in HG-NMIBC. Heatmap and dendrogram of 645	
differentially methylated gene promoter-associated CpG sites identified by array analysis. 646	
The dendrogram above the heatmap separates normal bladder (green bar, n=3) and high-647	
grade-NMIBC bladder tumours (red bar, n=21). Each row represents an individual CpG 648	
locus, and each column represents a normal control or tumour sample (listed beneath the 649	
heatmap). The colour scale beneath the heatmap represents methylation status: 650	
unmethylated is yellow (β-value=0.0), and fully methylated is blue (β-value=1.0). 651	
 652	
Figure 3. Heatmap for 25 hypermethylated gene promoter-associated CpG islands. 653	
Pyrosequencing validation of 25 gene promoter-associated CpG islands, identified as 654	
frequently differentially methylated in high-grade tumours by 450k BeadChip-array analysis. 655	
As indicated above the heatmap, the four normal bladder controls are presented to the left-656	
side of the heatmap, followed by 18 low-intermediate-grade tumours, and 51 high-grade 657	
tumours (the combined discovery and investigation cohorts). Each row represents the 658	
promoter-associated CpG island of the indicated gene, and each colour block the mean level 659	
of methylation across the island. The colour scale beneath the heatmap represents 660	
methylation status: unmethylated is green (0.0% methylation), and fully methylated is red 661	
(100.0% methylated). 662	
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Figure 4. Mean levels of methylation in high-grade tumours relative to low-663	
intermediate-grade tumours and normal bladder. Top ten genes showing an increase in 664	
mean level of methylation (solid red bar) in high-grade tumours (HG, n=51) relative to low-665	
intermediate-grade tumours (LG, n=18) and in comparison to normal bladder controls (C, 666	
n=4). Each individual control or tumour sample is shown as an unfilled blue circle. Significant 667	
differences in the mean levels of methylation between the low-intermediate- and high-grade 668	
tumours, or between control and low-intermediate-grade tumours, are indicated by *, p<0.05, 669	
or **, p<0.005 (Student’s T-test). 670	
 671	
Figure 5. Association of methylation with gene transcript expression in HG-NMIBC. 672	
Tumour transcript expression in unmethylated (UM, unfilled circles) and methylated (M, filled 673	
circles) high-grade tumours, relative to normal bladder control (C, unfilled triangles) for the 674	
four genes showing significant Spearman’s correlation coefficients between promoter 675	
methylation and gene expression (PON3, STAT5a, VAX2 and ARHGEF4; p=0.0006, 676	
p=0.005, p=0.013 and p=0.0007, respectively). The double-headed arrow represents the 677	
threshold for 3-fold reduced expression relative to the mean of the normal controls (solid 678	
blue bar); expression at or below this threshold signifies reduced expression in tumour 679	
samples.  680	
 681	
 682	
  683	
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Tables 684	
 685	
 
METHYLATION	
	FREQUENCY  
MEAN	LEVEL	OF	
METHYLATION  
Gene	
Symbol 
High-grade Low-intermediate-
grade 
 High-grade Low-intermediate-
grade 
 
 Number			(%) Number			(%) P	value (%) (%) P	value 
ATP5G2 37/51		(72.5) 6/18		(33.3) 0.005 51.04 30.20 0.029 
VAX2 13/51		(25.5) 0/18		(0.0) 0.015 32.31 19.56 0.004 
IRX1 37/51		(72.5) 8/18		(44.4) 0.045 49.47 38.70 0.067 
INSRR 29/51		(56.9) 5/18		(27.8) 0.054 24.06 24.06 0.028 
IRF8 25/51		(49.0) 4/18		(22.2) 0.057 26.13 17.99 0.157 
PRDM14 45/51		(88.2) 12/18		(66.7) 0.066 60.14 46.06 0.029 
VSX1 44/51		(86.3) 12/18		(66.7) 0.086 56.37 38.26 0.0004 
TFAP2b 22/51		(43.1) 4/18		(22.2) 0.160 32.25 17.68 0.047 
PRRX1 27/51		(52.9) 7/18		(38.9) 0.413 47.03 34.36 0.041 
HIST1H4F 42/51		(82.4) 13/18		(72.2) 0.496 59.46 41.91 0.017 
 686	
Table 1. Genes showing the greatest methylation increase in high-grade relative to 687	
low-intermediate-grade NMIBC tumours. Top ten genes showing an increase in frequency 688	
of methylation (left side of table), and/or an increase in mean level of methylation (right side 689	
of table) in high-grade tumours relative to low-intermediate-grade tumours. For the left side 690	
of the table, the number and proportion of tumours methylated are displayed for the low-691	
intermediate- and high-grade cohorts, with p-value (Fishers exact, p<0.05 significant). For 692	
the right side of the table, the mean level of methylation across the low-intermediate- and 693	
high-grade tumour cohorts are displayed with p-value (Student’s T-Test, p<0.05 significant). 694	
Statistically significant p-values are displayed in bold. 695	
28	
	
Supplemental Data 696	
 697	
Figure S1. Technical validation of 450k BeadChip-array data. Correlation between array-698	
derived β-values (x-axis) and methylation percentage as determined by Pyrosequencing (y-699	
axis) for 5 CpGs (cg07778029, cg14456683, cg01227537, cg05661282 and cg26465391) 700	
across 24 samples is shown. Spearman-rank correlation coefficient r=0.912; p<0.00001. 701	
 702	
Table S1. Sample characteristics. 703	
 704	
Table S2. List of 256 differentially methylated genes. 705	
 706	
Table S3. Methylation in discovery and investigation high-grade tumour cohorts. 707	
 708	
Table S4. Frequency and mean levels of methylation in 25 genes for high- and low-709	
intermediate-grade tumours. 710	
 711	
Table S5. Gene Ontology and KEGG pathway annotation lists. 712	
 713	
Table S6. Primer sequences.	714	
 715	
 716	
 717	
